Article info
PDFNeurological rarities
Globular glial tauopathy type II
- Correspondence to Professor Thomas T Warner, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK; t.warner{at}ucl.ac.uk
Citation
Globular glial tauopathy type II
Publication history
- Accepted October 26, 2022
- First published November 21, 2022.
Online issue publication
October 18, 2023
Article Versions
- Previous version (20 March 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Molecular pathology of neurodegenerative diseases: principles and practice
- Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review
- Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease
- Neuropathology and emerging biomarkers in corticobasal syndrome
- Fluid biomarkers in frontotemporal dementia: past, present and future
- Therapeutic trial design for frontotemporal dementia and related disorders
- Predictors of survival in frontotemporal lobar degeneration syndromes
- Pathology of neurodegenerative disease for the general neurologist
- [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
- Neuronal network disintegration: common pathways linking neurodegenerative diseases